2019
Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis
Banini BA, Cazanave SC, Yates KP, Asgharpour A, Vincent R, Mirshahi F, Le P, Contos MJ, Tonascia J, Chalasani NP, Kowdley KV, McCullough AJ, Behling CA, Schwimmer JB, Lavine JE, Sanyal AJ. Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. Journal Of Clinical Gastroenterology 2019, 53: 750-758. PMID: 30586008, PMCID: PMC6588507, DOI: 10.1097/mcg.0000000000001142.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver disease activity scoreNonalcoholic steatohepatitisLiver enzymesHistologic responseHp genotypeVitamin ENonalcoholic fatty liver diseaseResolution of steatohepatitisSignificant histologic improvementDisease Activity ScoreFatty liver diseaseHp 1 alleleRegression analysisEffect of VitEHaptoglobin 2 alleleDifferential treatment effectsGreater histologicCardiovascular outcomesHistologic improvementDiabetes mellitusLaboratory markersActivity scoreLiver diseaseHistologic featuresFibrosis stageVitamin E in Nonalcoholic Fatty Liver Disease
Banini B, Sanyal A. Vitamin E in Nonalcoholic Fatty Liver Disease. Nutrition And Health 2019, 311-323. DOI: 10.1007/978-3-030-05315-4_23.ChaptersNonalcoholic fatty liver diseaseVitamin E supplementationChronic liver diseaseFatty liver diseaseNonalcoholic steatohepatitisLiver diseaseE supplementationVitamin ESubtype of NAFLDAnnual direct medical costsChronic viral hepatitisAlcoholic liver diseaseClinical practice guidelinesDirect medical costsLong-term useNAFLD patientsLabel treatmentViral hepatitisPharmacological therapyComplex pathogenesisHistological featuresLiver fibrosisClinical trialsLeading causeClinical studies
2016
Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options
Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clinical Medicine Insights Therapeutics 2016, 8: cmt.s18885. PMID: 28670148, PMCID: PMC5491796, DOI: 10.4137/cmt.s18885.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNonalcoholic fatty liver diseaseLiver diseaseManagement of NAFLDPathogenesis of NAFLDAdvanced phase clinical trialsLiver-related outcomesCornerstone of treatmentFirst-line therapyHigh-risk patientsChronic liver diseaseFatty liver diseaseCurrent treatment optionsHepatic manifestationNAFLD patientsMetabolic syndromeMajor etiologyInsulin resistancePharmacologic interventionsTreatment optionsClinical evaluationClinical trialsHigh riskVitamin ENatural historyPatients